To assess whether the presence of the non-driver POLE variants was reflected in the nature of observed oncogenic driver mutations, we analyzed the molecular features of each individual group per cancer type in the CLS dataset (Fig. 3, colorectal cancer, and endometrial cancer; Supplementary Fig. S3; ovarian cancer; Supplementary Table S1 for all the data in the figures). This evidence concerns the gene POLE and ovarian cancer.